Renoprotezione farmacologica nella nefropatia cronica proteinurica

TL;DRAbstract

Background. Proteinuria of Chronic Kidney Disease (CKD) is frequently associated to
\ndyslipidemia, that increases the risk of renal and cardiovascular events. This might be
\nameliorated by drugs, such as ACEi or ARB, which effectively reduce proteinuria.
\nMoreover, clinical and experimental studies provided evidence that statin exerts
\nrenoprotective effect, but their role in renal outcomes is still unclear.
\nMethods. In this prospective, randomized trial, we evaluated if statin, combined to ACEi
\nand ARB, more effectively than ACEi/ARB alone reduce proteinuria, and if this effect
\ntranslate in a reduction of renal function decline. After 2 months of Benazepril/Valsartan
\ncombined therapy, 186 patients were randomized to 6 months Fluvastatin (80 mg/die)
\nYES or NO additional therapy.
\nResults. Benazepril/Valsartan therapy significantly and safely reduced proteinuria, total
\nand LDL cholesterol. Fluvastatin addition optimised blood

Chat with Paper

AI Agents for this Paper